Investigational Drug Details
| Drug ID: | D220 |
| Drug Name: | Clopidogrel |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00758 |
| DrugBank Description: | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213] |
| PubChem ID: | 60606 |
| CasNo: | 113665-84-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl |
| Structure: |
|
| InChiKey: | GKTWGGQPFAXNFI-HNNXBMFYSA-N |
| Molecular Weight: | 321.822 |
| DrugBank Targets: | P2Y purinoceptor 12 |
| DrugBank MoA: | Clopidogrel is metabolized to its active form by carboxylesterase-1.[A180508] The active form is a platelet inhibitor that irreversibly binds to P2Y<sub>12</sub> ADP receptors on platelets.[L7213] This binding prevents ADP binding to P2Y<sub>12</sub> receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation.[L7213] |
| DrugBank Pharmacology: | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] It has a long duration of action as it is taken once daily and a large therapeutic window as it is given in doses of 75-300mg daily.[L7213] |
| DrugBank Indication: | Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0521 | NCT01663103 | PHASE4 | COMPLETED | YES | 2012-08 | 2016-09-12 | Details |
| L0782 | NCT01739660 | PHASE1 | COMPLETED | NO | 2012-12 | 2013-10-25 | Details |
| L0886 | NCT01521494 | PHASE2 | COMPLETED | YES | 2012-01-11 | 2018-08-23 | Details |
| L0935 | NCT00912821 | PHASE4 | COMPLETED | NO | 2009-03 | 2016-10-13 | Details |
| L1478 | NCT05510323 | PHASE3 | RECRUITING | NO | 2024-02-01 | 2024-05-06 | Details |
| L1624 | NCT00277693 | PHASE4 | UNKNOWN | NO | 2006-01-16 | Details | |
| L1679 | NCT00642967 | PHASE3 | COMPLETED | NO | 2008-06 | 2021-09-14 | Details |
| L2305 | NCT06329674 | PHASE3 | COMPLETED | NO | 2021-04-27 | 2024-03-26 | Details |
| L3194 | NCT03738865 | PHASE3 | COMPLETED | YES | 2018-09-27 | 2020-05-22 | Details |
| L3243 | NCT06478186 | PHASE4 | RECRUITING | NO | 2024-08-16 | 2024-09-19 | Details |
| L3411 | NCT02317796 | PHASE2 | COMPLETED | NO | 2014-12 | 2016-09-26 | Details |
| L3634 | NCT06797869 | PHASE2 | RECRUITING | NO | 2025-01-29 | 2025-03-25 | Details |
| L3938 | NCT00359112 | PHASE3 | COMPLETED | NO | 2004-02 | 2009-05-18 | Details |
| L4096 | NCT02269735 | PHASE1 | COMPLETED | NO | 2014-11-26 | 2019-01-15 | Details |
| L4560 | NCT02481141 | COMPLETED | YES | 2014-07 | 2018-05-22 | Details | |
| L5449 | NCT01059799 | PHASE3 | COMPLETED | YES | 2010-02-01 | 2017-03-30 | Details |
| L5559 | NCT03088670 | PHASE3 | COMPLETED | NO | 2013-04-23 | 2017-03-23 | Details |
| L5837 | NCT01494987 | PHASE3 | COMPLETED | YES | 2012-01 | 2014-11-18 | Details |
| L6196 | NCT02198209 | PHASE4 | WITHDRAWN | NO | 2019-12 | 2019-09-30 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|